CXCL9 and CXCL10 are endogenous tumor angiogenesis inhibitors and high levels of CXCL9 and CXCL10 promote increasing numbers of tumor-infiltrating CD8+ T cells and reduce the level of cancer metastasis and improve survival rate of patients with ovarian or colon cancer (7, 22, 23). This evidence concerns the gene CXCL9 and cancer.